Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival
In a trial, Bristol Myers Squibb’s Opdivo improved disease-free survival in patients with esophageal cancer who had undergone surgery and chemotherapy.
